Metoprololsuccinat Stada (Metoprolol Tartrate)

Metoprolol is a selective β1‑adrenergic blocker used in several cardiovascular conditions.

• Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and heart attack.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain during exertion.
• Chronic heart failure: improves ventricular function and reduces hospitalization rates.
• Post‑myocardial infarction prophylaxis: lowers the chance of recurrent ischemic events and sudden cardiac death.

• Metoprolol selectively antagonises β1‑adrenergic receptors in cardiac tissue, inhibiting catecholamine‑induced stimulation. This reduces heart rate, myocardial contractility, and conduction velocity, leading to decreased cardiac output and lower arterial pressure while preserving β2‑mediated bronchial and vascular effects.

Metoprolol may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects

• Fatigue: persistent tiredness or lack of energy.
• Dizziness: light‑headed sensation, especially on standing.
• Bradycardia: heart rate slower than normal.
• Headache: mild to moderate cranial pain.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Hypotension: markedly low blood pressure with risk of syncope.
• Bronchospasm: narrowing of airways, particularly in patients with reactive airway disease.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for adverse events.

• Cardiovascular assessment: obtain baseline heart rate and blood pressure.
• Respiratory status: avoid in patients with uncontrolled asthma or COPD.
• Diabetes monitoring: watch for masking of hypoglycaemic symptoms.
• Concomitant drugs: review for interactions that may exacerbate bradycardia or hypotension.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Metoprolol can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Calcium channel blockers (e.g., verapamil, diltiazem): may cause profound bradycardia or heart block.
• Potassium‑sparing diuretics (e.g., spironolactone): increase risk of hyperkalemia.
• Antidepressants (e.g., fluoxetine): can raise plasma metoprolol levels.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect.
• Antidiabetic agents (e.g., insulin, sulfonylureas): monitor blood glucose as symptoms of hypoglycaemia may be masked.